Chromosome translocations in multiple myeloma
The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
Multiple myeloma (MM), a malignant tumor of somatically mutated, isotype-switched plasma cells (PC), usually arises from a common benign PC tumor called Monoclonal Gammopathy of Undetermined Significance (MGUS). MM progresses within the bone marrow, and then to an extramedullary stage from which MM cell lines are generated. The incidence of IgH translocations increases with the stage of disease: 50% in MGUS, 60-65% in intramedullarly MM, 70-80% in extramedullary MM, and >90% in MM cell lines. Primary, simple reciprocal IgH translocations, which are present in both MGUS and MM, involve many partners and provide an early immortalizing event. Four chromosomal partners appear to account for the majority of primary IgH translocations: 11q13 (cyclin D1), 6p21 (cyclin D3), 4p16 (FGFR3 and MMSET), and 16q23 (c-maf). They are mediated primarily by errors in IgH switch recombination and less often by errors in somatic hypermutation, with the former dissociating the intronic and 3' enhancer(s), so that potential oncogenes can be dysregulated on each derivative chromosome (e.g., FGFR3 on der14 and MMSET on der4). Secondary translocations, which sometimes do not involve Ig loci, are more complex, and are not mediated by errors in B cell specific DNA modification mechanisms. They involve other chromosomal partners, notably 8q24 (c-myc), and are associated with tumor progression. Consistent with MM being the malignant counterpart of a long-lived PC, oncogenes dysregulated by primary IgH translocations in MM do not appear to confer an anti-apoptotic effect, but instead increase proliferation and/or inhibit differentiation. The fact that so many different primary transforming events give rise to tumors with the same phenotype suggests that there is only a single fate available for the transformed cell.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Approximately 40% of multiple myeloma is characterized by the presence of trisomies in the neoplastic plasma cells (hyperdiploid multiple myeloma), while most of the rest have a translocation involving the immunoglobulin heavy chain (IgH) locus on chromosome 14q32 (IgH translocated multiple myeloma).38–41”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [39]
Citations
Cites
SEER Cancer Statistics Review, 1975-2003
Ries, L. A. G., Harkins, D., Krapcho, M. F., Mariotto, A. B., Miller, B., Feuer, E. J., Clegg, L. X., Eisner, M. P., Horner, M., Howlader, N., et al. (2006) · Digital Archive @ GSU · Cited by 11,774
Cancer: Principles and Practice of Oncology.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-819_4 · Cited by 8,516
Cancer: Principles and Practice of Oncology.
(1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-108-3-506_5 · Cited by 1,900
Dalla-Favera, R., Bregni, M., Erikson, J., Patterson, D., Gallo, R. C., & Croce, C. M. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.24.7824 · Cited by 1,773
Anderson, P. C. (1999) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.281.24.2351 · Cited by 1,006
Cellular Origin of Human B-Cell Lymphomas
Küppers, R., Klein, U., Hansmann, M.-L., & Rajewsky, K. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911113412007 · Cited by 715
The Proto-Oncogene c-maf Is Responsible for Tissue-Specific Expression of Interleukin-4
Ho, I.-C., Hodge, M. R., Rooney, J. W., & Glimcher, L. H. (1996) · Cell · doi:10.1016/s0092-8674(00)81299-4 · Cited by 667
Chesi, M., Nardini, E., Brents, L. A., Schröck, E., Ried, T., Kuehl, W. M., & Bergsagel, P. L. (1997) · Nature Genetics · doi:10.1038/ng0797-260 · Cited by 637 · cited 2×
“…of conventional cytogenetics, SKY analyses, metaphase FISH analyses, isolation of molecular clones, and RT±PCR assays (Bergsagel et al., 1996; Chesi et al., 1997, 1998a; Gabrea et al., 1999; Shaughnessy et al., 2001; Shou et al., 2000; Kuehl, 2001, unpublished results), we have identi®ed at…”
BackgroundSelf-citationChesi, M., Nardini, E., Lim, R. S. C., Smith, K. D., Kuehl, W. M., & Bergsagel, P. L. (1998) · Blood · doi:10.1182/blood.v92.9.3025 · Cited by 572
Self-citationDNA repair protein Ku80 suppresses chromosomal aberrations and malignant transformation
Difilippantonio, M. J., Zhu, J., Chen, H. T., Meffre, E., Nussenzweig, M. C., Max, E. E., Ried, T., & Nussenzweig, A. (2000) · Nature · doi:10.1038/35006670 · Cited by 547
Research works printed but not linked: 1
- Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, Edwards BK . 2000 SEER Cancer Statistics Review, 1973–1997 National Cancer Institute: Bethesda
Cited by
Items 301–400 of 545
Multiple Myeloma and Related Disorders
Rajkumar, S. V., & Dispenzieri, A. A. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-2865-7.00104-1 · Cited by 10
Still high risk? A review of translocation t(14;16) in multiple myeloma
Mian, H. S., Kaiser, M., & Fonseca, R. (2024) · American Journal of Hematology · doi:10.1002/ajh.27419 · Cited by 9
Mature B‐ and T‐cell Neoplasms and Hodgkin Lymphoma
Siebert, R. (2010) · Wiley eBooks · doi:10.1002/9781118010136.ch10 · Cited by 10
MYC Causes Multiple Myeloma Progression via Attenuating TP53-Induced MicroRNA-34 Expression
Murakami, Y., Kimura-Masuda, K., Oda, T., Matsumura, I., Masuda, Y., Ishihara, R., Watanabe, S., Kuroda, Y., Kasamatsu, T., Gotoh, N., et al. (2022) · Genes · doi:10.3390/genes14010100 · Cited by 9
Nayak, B. S., Mungrue, K., Gopee, D., Friday, M., Garcia, S., Hirschfeld, E., Grant, C., Henry, J., Chadband, A., Gardider, K., et al. (2011) · Archives of Physiology and Biochemistry · doi:10.3109/13813455.2011.582875 · Cited by 9
Lagler, C., El‐Mesery, M., Kübler, A. C., Müller-Richter, U. D. A., Stühmer, T., Nickel, J., Müller, T. D., Wajant, H., & Seher, A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0185720 · Cited by 9
Eμ/Sμ transposition into Myc is sometimes a precursor for T(12;15) translocation in mouse B cells
Kovalchuk, A. L., Kim, J. S., & Janz, S. (2003) · Oncogene · doi:10.1038/sj.onc.1206345 · Cited by 9
Handa, H., Sasaki, Y., Hattori, H., Alkebsi, L., Kasamatsu, T., Saitoh, T., Mitsui, T., Yokohama, A., Tsukamoto, N., Matsumoto, M., et al. (2017) · Oncology Letters · doi:10.3892/ol.2017.6672 · Cited by 8
Individualizing Therapy Using Molecular Markers in Multiple Myeloma
Bergsagel, P. L. (2007) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2007.s.019 · Cited by 8
Self-citationMcNeil, N. E., Kim, J. S., Ried, T., & Janz, S. (2005) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20172 · Cited by 10
Promiscuity of translocation partners in multiple myeloma
Martin, L. D., Belch, A. R., & Pilarski, L. M. (2010) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22499 · Cited by 8
Pathophysiology of myeloma bone disease
Oyajobi, B. O., & Mundy, G. R. (2004) · CRC Press eBooks · doi:10.1201/b13347-9 · Cited by 8
Multiple Myeloma and Related Disorders
Rajkumar, S. V., & Dispenzieri, A. A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00101-8 · Cited by 8
The Activating Protein-1 Transcriptional Complex: Essential and Multifaceted Roles in Bone
Yamashita, J., & McCauley, L. K. (2006) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1385/bmm:4:2:107 · Cited by 8
A xeno-transplantable plasma cell leukemia line with a split translocation of the IgH gene
Ohbayashi, K., Taniwaki, M., Ninomiya, M., Kiyoi, H., Iida, S., Ueda, R., & Naoe, T. (2003) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(02)00862-2 · Cited by 8
Anderson, K. C., & Dalton, W. S. (2002) · PubMed · Cited by 8
Possible Therapeutic Potential of Disulfiram for Multiple Myeloma
Drozdková, D. W., & Trtková, K. S. (2021) · Current Oncology · doi:10.3390/curroncol28030193 · Cited by 7
Martin, L. D., Harizanova, J., Righolt, C. H., Zhu, G., Mai, S., Belch, A. R., & Pilarski, L. M. (2013) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22049 · Cited by 7
Bioactive Compounds from Herbal Medicine Targeting Multiple Myeloma
Cotoraci, C. A., Ciceu, A., Sasu, A., Miuţescu, E., & Hermenean, A. O. (2021) · Applied Sciences · doi:10.3390/app11104451 · Cited by 7
Multicolor interphase cytogenetics for the study of plasma cell dyscrasias
Calasanz, M. J., Siebert, R., Schoch, R., Cigudosa, J. C., Martín-Subero, J. I., Odero, M. D., Prósper, F., & Sáez, B. (2007) · Oncology Reports · doi:10.3892/or.18.5.1099 · Cited by 8
Cap-Independent Translation in Hematological Malignancies
Horvilleur, E., Wilson, L. A., Bastide, A., Piñeiro, D., Pöyry, T. A. A., & Willis, A. E. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00293 · Cited by 7
Gmidène, A., Avet‐Loiseau, H., Sennana, H., Abdallah, I. B., Khlif, A., Meddeb, B., Elloumi, M., & Saad, A. (2011) · Cytogenetic and Genome Research · doi:10.1159/000334878 · Cited by 6
Molecular heterogeneity and centrosome-associated genes in multiple myeloma
Kryukov, F., Němec, P., Dementyeva, E., Kubiczková, L., Ihnatová, I., Budínská, E., Jarkovský, J., Ševčíková, S., Kuglík, P., & Hájek, R. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.764416 · Cited by 6
Disease heterogeneity, prognostication and the role of targeted therapy in multiple myeloma
Zanwar, S., & Kumar, S. K. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1957875 · Cited by 6
FGF signaling inhibits the proliferation of human myeloma cells and reduces c-myc expression
Firme, L., & Bush, A. B. (2003) · BMC Cell Biology · doi:10.1186/1471-2121-4-17 · Cited by 6
Studies of four new human myeloma cell lines
Karpas, A., Harder, L., Czepulkowski, B. H., Bloxham, D. M., Saward, R., Dremucheva, A., & Siebert, R. (2004) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190400002244 · Cited by 6
Qian, S., Somlo, G., Zhou, B., & Yen, Y. (2005) · PubMed Central · Cited by 6
Hwang, W. Y. K., Gullo, C. A., Shen, J., Poh, C. K., Tham, S.-M., Cow, G., Au, M., Chan, E. W. E., & Teoh, G. (2006) · Leukemia · doi:10.1038/sj.leu.2404099 · Cited by 6
Teitell, M. A., & Pandolfi, P. P. (2004) · Wiley eBooks · doi:10.1002/0471675067.mmc014 · Cited by 6
Multiple Myeloma: 2026 Update on Diagnosis, Risk‐Stratification and Management
Rajkumar, S. V. (2026) · American Journal of Hematology · doi:10.1002/ajh.70475 · Cited by 5
Epigenetic Alterations as Vital Aspects of Bortezomib Molecular Action
Kulig, P., Łuczkowska, K., Bakinowska, E., Baumert, B., & Machaliński, B. (2023) · Cancers · doi:10.3390/cancers16010084 · Cited by 5
Analysis of chromosome 12p deletion in plasma cell dyscrasias
Jiang, N., Qi, C. X. Y., Yu, L., Ning, Y., An, G., Qiu, L., & Chang, H. (2011) · Leukemia Research · doi:10.1016/j.leukres.2011.07.030 · Cited by 5
Mak, T. W., & Saunders, M. E. (2006) · Elsevier eBooks · doi:10.1016/b978-012088451-3.50032-6 · Cited by 5
Tosi, P., Terragna, C., Testoni, N., Zamagni, E., Renzulli, M., Tacchetti, P., Montanari, E., Perrone, G., Ceccolini, M., Brioli, A., et al. (2007) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2007.00974.x · Cited by 5
Kovalchuk, A. L., & Janz, S. (2002) · International Journal of Cancer · doi:10.1002/ijc.10638 · Cited by 5
Prognostic value of 1q21 amplification in multiple myeloma
Abramova, T. V., Обухова, Т. Н., Менделеева, Л. П., Pokrovskaya, O. S., Грибанова, Е. О., Рыжко, В. В., Grebenyuk, L. A., Nareyko, M. V., Solovev, M. V., Votyakova, O. M., et al. (2017) · Terapevticheskii arkhiv · doi:10.17116/terarkh201789732-38 · Cited by 5
Otsuki (2011) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2011.648 · Cited by 4
Serin, İ., Colak, Y., Oyacı, Y., Tunçel, F. C., Pehlıvan, M., & Pehlıvan, S. (2023) · Cytokine · doi:10.1016/j.cyto.2023.156401 · Cited by 4
Laganà, A. (2024) · Lecture notes in computer science · doi:10.1007/978-3-031-55248-9_8 · Cited by 4
Sáez, B., Martín-Subero, J. I., Lahortiga, I., Largo, C., Larráyoz, M. J., Odero, M. D., Prósper, F., Cigudosa, J. C., Siebert, R., & Calasanz, M. J. (2007) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2006.12.009 · Cited by 4
Light-chain plasma cell myeloma caused by 14q32/IGH translocation and loss of the other allele
Nishio, Y., Sakai, H., Saiki, Y., Uchida, A., Uemura, Y., Matsunawa, M., Isobe, Y., Kato, M., Tomita, N., & Miura, I. (2019) · International Journal of Hematology · doi:10.1007/s12185-019-02629-7 · Cited by 4
Jirabanditsakul, C., Dakeng, S., Kunacheewa, C., U‐pratya, Y., & Owattanapanich, W. (2022) · Technology in Cancer Research & Treatment · doi:10.1177/15330338221111228 · Cited by 4
Cytokines and Signal Transduction in Multiple Myeloma
Chauhan, D., & Anderson, K. C. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3764-2_27 · Cited by 4
Classical and Molecular Cytogenetic Analysis of Hematolymphoid Disorders
Micale, M. A. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-262-9_2 · Cited by 4
The Molecular Biology of Multiple Myeloma
Bergsagel, P. L. (2005) · Wiley eBooks · doi:10.1002/9780470987063.ch11 · Cited by 4
Self-citationKyrtsonis, M., Koulieris, E., Bartzis, V., Pessah, I., Nikolaou, E., Karalis, V., Maltezas, D., Panayiotidis, P. G., & Stephen, J. (2013) · InTech eBooks · doi:10.5772/55855 · Cited by 4
Ramina, R., & Tatagiba, M. S. (2016) · Springer eBooks · doi:10.1007/978-3-319-43368-4_11 · Cited by 4
Multiple Myeloma and Related Disorders
Rajkumar, S. V., & Dispenzieri, A. A. (2008) · Elsevier eBooks · doi:10.1016/b978-0-443-06694-8.50114-7 · Cited by 4
Sáez, B., Martín-Subero, J. I., Odero, M. D., Prósper, F., Hernández, R. S., Cigudosa, J. C., Siebert, R., & Calasanz, M. J. (2006) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2005.12.008 · Cited by 4
The treatment of multiple myeloma in an era of precision medicine
Kint, N., Vlayen, S., & Delforge, M. (2019) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2019.1606672 · Cited by 4
Rudolph, C., Liehr, T., Steinemann, D., Emura, M., Daibata, M., Matsuo, Y., Emi, N., Abe, M., Lai, R. L., Mrasek, K., et al. (2006) · Cytogenetic and Genome Research · doi:10.1159/000089873 · Cited by 4
Guan, Q., Yu, J., Pan, J., Fan, Y., Ji, J., Zhao, R., Liu, Z., Liu, B., Wu, L., & Sun, D. (2025) · Advanced Science · doi:10.1002/advs.202518277 · Cited by 3
Seth, N., Naing, P. T., Singh, R., Geetha, S. D., Reddy, K., Zhang, X., Yang, T., Caro, J., & Tam, W. (2025) · Pathobiology · doi:10.1159/000546669 · Cited by 3
Sumekar, T. A., Ashrani, A. A., Winarni, T. I., & Hagerman, R. J. (2011) · Case Reports in Genetics · doi:10.1155/2011/143132 · Cited by 3
Immunoglobulin and MYC Rearrangements in Multiple Myeloma Pathogenesis
Bergsagel, P. L., & Kuehl, W. M. (2015) · Springer eBooks · doi:10.1007/978-3-319-19983-2_8 · Cited by 3
Self-citationDoes myeloma genetic have an effect on stem cell mobilization?
Başçı, S., Yiğenoğlu, T. N., Yaman, S., Bozan, E., Ulu, B. U., Bakırtaş, M., Kılınç, A., Özcan, N., Bahsi, T., Dal, M. S., et al. (2021) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2021.103249 · Cited by 3
Assessment of Bone Marrow Biopsy and Cytogenetic Findings in Patients with Multiple Myeloma
Şeyhanlı, A., Yavuz, B., Akşit, Z., Yüce, Z., Özkal, Ş., Altungöz, O., Demırkan, F., Alacacıoğlu, İ., & Özsan, G. H. (2021) · Turkish Journal of Hematology · doi:10.4274/tjh.galenos.2021.2021.0325 · Cited by 3
Kim, S., Kim, J. H., Lee, D. M., Lee, S., Oh, S. Y., Kwon, H.-C., Kim, K.-E., Han, J., & Kim, H. (2009) · The Korean Journal of Hematology · doi:10.5045/kjh.2009.44.1.14 · Cited by 3
Transformation maligne des gammapathies monoclonales de signification indéterminée
Decaux, O., Avet‐Loiseau, H., & Grosbois, B. (2007) · La Presse Médicale · doi:10.1016/j.lpm.2007.01.040 · Cited by 3
Sato, K., Sakai, H., Kato, M., Nishio, Y., Tsuruoka, Y., Uemura, Y., Yokoi, S., SAITO, T., Matsunawa, M., Suzuki, Y., et al. (2015) · International Journal of Hematology · doi:10.1007/s12185-015-1749-5 · Cited by 3
Heterogeneity and Plasticity of Multiple Myeloma
Šváchová, H., Ševčíková, S., & Hájek, R. (2013) · InTech eBooks · doi:10.5772/55365 · Cited by 3
H2AFX Polymorphisms Are Associated with Decreased Risk of Diffuse Large B Cell Lymphoma in Koreans
Jin, X. M., Kim, H. N., Shin, M., Lee, I.-K., Lee, J. S., Lee, J.-H., Kim, H., Choi, J., Juhng, S. W., & Choi, C. (2011) · DNA and Cell Biology · doi:10.1089/dna.2010.1130 · Cited by 3
Monoclonal Gammopathy of Undetermined Significance
Patricia, M., Álvarez, R., Maldonado, J., Vinet, R., & Barri, K. (2013) · InTech eBooks · doi:10.5772/56138 · Cited by 3
Advances in Myeloma Genetics and Prospects for Pharmacogenomic Testing in Multiple Myeloma
Claudio, J. O., & Stewart, A. K. (2005) · American Journal of PharmacoGenomics · doi:10.2165/00129785-200505010-00003 · Cited by 3
Reyes-Sánchez, A. A., & Obil-Chavarría, C. A. (2016) · Journal of Spine · doi:10.4172/2165-7939.1000295 · Cited by 2
Alterações moleculares no Mieloma Múltiplo
Braggio, E., & Renault, I. Z. (2007) · Revista Brasileira de Hematologia e Hemoterapia · doi:10.1590/s1516-84842007000100004 · Cited by 2
Hematopoietic Cell Transplantation for Multiple Myeloma
Qazilbash, M. H., & Giralt, S. (2009) · Wiley eBooks · doi:10.1002/9781444303537.ch58 · Cited by 2
Dib, A., Glebov, O. K., Shou, Y., Singer, R. H., & Kuehl, W. M. (2008) · DNA repair · doi:10.1016/j.dnarep.2008.11.010 · Cited by 2
Self-citationCytokines in Multiple Myeloma: Therapeutic Implications
Chauhan, D., Hideshima, T., & Anderson, K. C. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-455-1_10 · Cited by 2
Mujer de 74 años con dolor en la ingle derecha y osteólisis craneal
García‐Sánz, R., Rozman, M., & Tomàs, X. (2003) · Medicina Clínica · doi:10.1016/s0025-7753(03)73780-4 · Cited by 2
Mature B‐ and T‐cell neoplasms and Hodgkin lymphoma
Siebert, R., & Aukema, S. (2015) · Wiley eBooks · doi:10.1002/9781118795569.ch11 · Cited by 2
Facon, T. T. F., Yakoub‐Agha, I., & Leleu, X. P. (2003) · Encyclopédie médico-chirurgicale. Hématologie · doi:10.1016/s1155-1984(03)00047-5 · Cited by 2
Molekulare Pathologie von Plasmazellneoplasien
Fend, F. (2010) · Der Pathologe · doi:10.1007/s00292-010-1375-1 · Cited by 2
Distribución de tipos de paraproteínas en una muestra de enfermos con mieloma múltiple
Hernández, A. A. A., Villaescusa-Blanco, R., Morera-Barrios, L. M., González, Y. J., Merlín-Linares, J. C., Ramón-Rodríguez, L., & Hernández-Padrón, C. (2013) · Revista cubana de hematología, inmunología y hemoterapia · Cited by 2
Atrash, S., Zhang, Q., Papanikolaou, X. D., Stein, C., Abdallah, A.-O. A., & Barlogie, B. (2017) · Journal of Global Oncology · doi:10.1200/jgo.2016.008003 · Cited by 2
Cytogenetic Profiling of Myelomas, Association With Complete Blood Count: Study of 180 Patients
Tarigopula, A., Chandrashekar, V., & Govindasamy, P. (2017) · Laboratory Medicine · doi:10.1093/labmed/lmx066 · Cited by 2
Nosologie et prise en charge des gammapathies monoclonales
Grosbois, B., Decaux, O., Guenet, L., Goasguen, J. E., & Jégo, P. (2009) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)32498-7 · Cited by 2
Bakthavatchalu, V., & Muthupalani, S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.64253-8 · Cited by 2
Joshua, D., Ho, P. J., Gibson, J., & Brown, R. D. (2004) · CRC Press eBooks · doi:10.1201/b13347-6 · Cited by 2
Molecular Genetics of Multiple Myeloma
Bi, C., & Chng, W.-J. (2010) · Wiley eBooks · doi:10.1002/9780470015902.a0022446 · Cited by 2
Cytogenetic aberrations in neuropathy associated with IgM monoclonal gammopathy
Eurelings, M., Lokhorst, H. M., Notermans, N. C., Krijtenburg, P. J., van Kessel, B., Eleveld, M. J., Bloem, A. C., Wokke, J. H. J., Poot, M., & Buijs, A. (2007) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2007.04.022 · Cited by 2
Multiple Myeloma and Its Treatment
Brant, J. M., & Felder, B. (2002) · Clinical journal of oncology nursing · doi:10.1188/02.cjon.359-362 · Cited by 2
Kaya, E. A., Baughn, L. B., Pham, T. T., Ketterling, R. P., Kumar, S. K., & Jevremović, D. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1821012 · Cited by 1
Baďurová, K., Kapustová, V., Kotulová, J., Brinsa, V., Piherová, L., Janoušek, V., Pohludka, M., Richtář, M., Jelínek, T., Hájek, R., et al. (2026) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-026-00836-7 · Cited by 1
Carretero-Fernández, M., Cabrera-Serrano, A. J., Ruiz-Durán, L., Ibáñez, M., Bonilla, M., Mesa, F., Gutiérrez‐Bautista, J. F., Chahboun, R., Reyes‐Zurita, F. J., Martínez‐López, J., et al. (2026) · Translational Oncology · doi:10.1016/j.tranon.2026.102796 · Cited by 1
Genomic Strategies Determining Progression from MGUS to Multiple Myeloma
Braggio, E., & Fonseca, R. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4666-8_1 · Cited by 1
Molecular Pathology of Plasma Cell Neoplasms
Cook, J. R. (2010) · Molecular pathology library · doi:10.1007/978-1-4419-5698-9_19 · Cited by 1
[Genetic tools for risk-stratification in multiple myeloma].
Braggio, E., & Garramuño, F. A. (2013) · PubMed · Cited by 1
Kaizu, K., Nakazato, H., Yata, K., Otsuki, T., Sugihara, T., Amagasa, T., & Sato, Y. (2004) · Oral Medicine & Pathology · doi:10.3353/omp.9.103 · Cited by 1
Karyotypic variability of human multiple myeloma cell lines
Турилова, В. И., & Smirnova, T. D. (2012) · Cell and Tissue Biology · doi:10.1134/s1990519x12050136 · Cited by 1
Sikuyayenga, M. J., Reeder, C. B., & Mikhael, J. R. (2012) · Leukemia Research Reports · doi:10.1016/j.lrr.2012.09.003 · Cited by 1
Novel chromosomal translocations in multiple myeloma: t(13;16)(q14;q24) and t(1;15)(q10;q26)
Akalın, İ., KUTLAY, N. Y., İlhan, O., & Tükün, A. (2007) · International Journal of Laboratory Hematology · doi:10.1111/j.1751-553x.2006.00837.x · Cited by 1
Tonon, G., & Anderson, K. C. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4066-6.00030-5 · Cited by 1
Bakthavatchalu, V., & Muthupalani, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95488-4.00057-7 · Cited by 1
Molecular Classification and Risk Stratification
Kumar, S. K., Fonseca, R., & Stewart, K. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8520-9_6 · Cited by 1
Cyclins D in Regulation and Dysregulation of the Cell Cycle in Multiple Myeloma
Kubiczková, L., Dúcka, M., Sedlaříková, L., Kryukov, F., Hájek, R., & Ševčíková, S. (2013) · Klinicka onkologie · doi:10.14735/amko2013313 · Cited by 1
Etiologia i patogeneza szpiczaka plazmocytowego
Iskierka‐Jazdzewska, E., & Jamroziak, K. (2015) · Hematologia · doi:10.5603/hem.2015.0037 · Cited by 1
Gorczyca, W. (2010) · CRC Press eBooks · doi:10.3109/9781841847443-14 · Cited by 1
Ubiquitination and DNA Repair in Multiple Myeloma
Crawford, L., & Irvine, A. E. (2018) · InTech eBooks · doi:10.5772/intechopen.70800 · Cited by 1
Choudhury, S. R., & Walker, B. A. (2019) · RNA technologies · doi:10.1007/978-3-030-14792-1_22 · Cited by 1
Metadata
- Authors
- Bergsagel, P. L., & Kuehl, W. M.
- Affiliations
- Cornell University (US)
- National Cancer Institute (US)
- Corresponding author
- Bergsagel, P Leif
- ORCID
- Bergsagel, P Leif
- Venue
- Oncogene
- Published
- 2001-09-10
- Volume
- 20
- Issue
- 40
- Pages
- 5611-5622
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W1977707370
- Cited by
- 478
- References
- 64
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 7 · 2023: 16 · 2022: 17 · 2021: 16 · 2020: 13 · 2019: 12 · 2018: 11 · 2017: 15 · 2016: 17 · 2015: 21 · 2014: 16 · 2013: 26 · 2012: 19
- FWCI
- 4.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Keywords
- multiple myeloma, chromosomal translocation, immunoglobulin heavy chain locus, monoclonal gammopathy of undetermined significance, cyclin D1, cyclin D3, FGFR3, MMSET, c-Maf, c-Myc, somatic hypermutation, tumor progression, extramedullary myeloma
- MeSH terms
- Cell Line, Transformed, Chromosomes, Chromosomes, Human, Pair 11, Chromosomes, Human, Pair 16, Chromosomes, Human, Pair 4, Chromosomes, Human, Pair 6, Chromosomes, Human, Pair 8, Humans, Immunoglobulins, Models, Genetic, Multiple Myeloma, Phenotype, Translocation, Genetic, Tumor Cells, Cultured, Gene Expression Regulation, Neoplastic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.